What We Do

KIDS V CANCER promotes pediatric cancer research by identifying structural impediments at key junctures in the research process – new drugs, tissue donation and access to funding – and developing strategies to address them. Since Nancy Goodman formed Kids v Cancer in 2009:

  • CREATING HOPE ACT: We authored and championed the Creating Hope Act, which was passed into law in 2012 as part of the 2012 FDA Safety and Innovation Act, 21 U.S.C. 360ff. The Creating Hope Act provides a market-based incentive to spur pediatric cancer drug development in the form of pediatric priority review vouchers.
  • Under the Creating Hope Act, three vouchers were awarded, including Unituxin for neuroblastoma, the most exciting advance in neuroblastoma treatment in 40 years.   In December, 2014, a voucher sold for $125M.
  • Kids v Cancer is working with the FDA and has provided comments to finalize the guidance on the Creating Hope Act program.
  • ADVANCING HOPE ACT: Kids v Cancer authored the Advancing Hope Act, H.R. 1537, which will permanently reauthorize the Creating Hope Act. Congressmen Butterfield, McCaul and Van Hollen introduced the Advancing Hope Act on March 25, 2015.
  • KIDS’ INNOVATIVE DRUGS INITIATIVE (KIDS): Kids v Cancer has authored KIDS to reform PREA and BPCA to help kids with cancer get access to the most promising therapies available, even if they are unapproved drugs for adult cancers, or have been abandoned for adult cancers.
  • COMPASSIONATE USE: Kids v Cancer participated in the #SAVEJOSH campaign to seek compassionate use access to Chimerix’s brincidofovir and has hosted workshops and published commentaries on compassionate use for children with cancer.
  • AUTOPSY TISSUE DONATION PROGRAM: We have an autopsy tissue donation program to facilitate post mortem pediatric CNS tumor tissue to science.
  • PRESIDENTIAL DECLARATIONS: Kids v Cancer successful requested that September be declared as National Childhood Cancer Awareness Month for each year since 2010.
  • EUROPE: Kids v Cancer is working with a team of European regulators, industry, scientists and advocates to propose incentives for pediatric cancer drug development under European Union law.

Comments are closed.